US regulators back multi-cancer blood test – but Hong Kong doctors remain cautious
US regulators have endorsed multi-cancer early detection (MCED) blood tests for the first time. A US Food and Drug Administration (FDA) panel voted to recommend Grail's Galleri test for premarket approval. This marks a landmark decision for the emerging field. The tests aim to find cancer signs in healthy individuals by analyzing abnormal molecules in bodily fluids.
The FDA panel's vote for Grail's Galleri test is a significant step for MCED technology. It validates the concept of detecting multiple cancers from a single blood sample. This regulatory backing could accelerate research and development in the field, moving these tests closer to wider clinical use.
For Hong Kong, the immediate impact is limited. Doctors there remain cautious about the clinical value of MCED tests. Wider adoption in Hong Kong faces challenges, despite growing interest. Local healthcare providers will demand more data before integrating these tests into standard practice.
The thing to watch is how Asian regulators respond. If a major Asian market like China or Japan grants similar premarket approval, it would signal a faster path to adoption across the region. This would open new market opportunities for companies developing these diagnostics.
Share this article
Related reading
6 stories
The most dangerous AI claims aren’t wrong — they’re overstated

I Built an AI Safety Layer on a 4GB Phone

Don't let the AI change its own pass condition: pick the protected files, stop on any change

Your SKILL.md is portable. Is its behavior? Introducing Skillporter

GPT-6.2 Sol vs. Claude Opus 5.5: Not as accurate, but still might be the better buy

